RAGE antagonist peptide acetate NEW
| Price | $85 | $248 | $372 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: RAGE antagonist peptide acetate | Purity: 97.17% |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | RAGE antagonist peptide acetate |
| Description | RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. |
| In vitro | In cancer cells, RAGE antagonist peptide acetate reduces the ability of the ligands to stimulate RAGE activation of NFκB[2]. |
| In vivo | In mice bearing asthma, RAGE antagonist peptide acetate (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide acetate also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function[1]. RAGE antagonist peptide acetate reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth. RAGE antagonist peptide acetate (100 μg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo[2]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | RAGE antagonist peptide acetate | RAGE antagonist peptide Acetate |
| Inhibitors Related | Anle138b | BSBM7 | Notoginsenoside R1 | Geniposide | Deferoxamine Mesylate | Tramiprosate | Dihydroergocristine mesylate | Rutin | Methyl tridecanoate | DAPT |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Peptide Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $595.00/2mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1gram |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2024-05-21 | |
| $117.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY